New research into the blood vessels within colorectal tumors may offer insights into patient prognosis, suggesting that tumor vasculature profiles could become a valuable tool for predicting outcomes. The study, published in JAMA Network Open, analyzed data from 837 patients with colorectal cancer (CRC) and identified distinct patterns in blood vessel characteristics linked to survival.
Blood Vessel Density and Survival
Researchers used multispectral immunofluorescence and computational image analysis to examine tumor samples from patients enrolled in the Nurses’ Health Study and Health Professionals Follow-up Study. During long-term follow-up, 263 patients died from CRC. Those with the highest overall density of CD34-positive blood vessels in their tumors faced a 61% lower risk of CRC-specific death compared to patients with the lowest density, after adjusting for other factors. A greater proportion of small CD34-positive vessels also correlated with better survival, with the highest group showing a 52% lower risk of death.
It is clear that increased blood vessel presence does not directly protect against cancer. Instead, vessel density may reflect broader characteristics of the tumor microenvironment. Blood vessels can support tumor growth by delivering oxygen and nutrients, but they also enable immune cells to infiltrate tumors and improve drug delivery.
Specific Vessel Types and Risk
Further analysis revealed that certain vessel subtypes were linked to worse outcomes. Patients with the highest proportion of CD34+CD36+ vessels had a 58% higher risk of CRC-specific death, while those with the most CD34+LAMB1+ vessels faced a 78% higher risk. These markers identify endothelial cell types involved in angiogenic sprouting, the process of forming new blood vessels. An abundance of these vessels may signal active angiogenesis and other tumor-promoting processes.
The findings highlight that tumor blood vessels are not biologically uniform. Their molecular profiles, rather than mere quantity, carry prognostic significance. This distinction could refine precision cancer profiling by adding vascular characteristics to existing molecular and pathological biomarkers.
These vascular profiles might also identify patients with more aggressive disease and guide research into new therapeutic targets. However, the study was observational and cannot confirm that specific vessel features directly influence survival. Validation in additional populations is needed before clinical application.
